BRIDGEWATER, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on developing orphan treatments for rare pulmonary diseases, today reported that three ARIKAYCE™ abstracts and three INS1009 abstracts will be presented at the American Thoracic Society (ATS) 2015 International Conference taking place in Denver from May 15 – 20. ARIKAYCE, or liposomal amikacin for inhalation, is in late-stage development for the treatment of adult patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC).
Help employers find you! Check out all the jobs and post your resume.
